News

The agreement provides Prolexys with exclusive, worldwide rights to a patent estate covering selective anti-tumor compounds discovered by Dr Brent Stockwell, a former Whitehead fellow and now an

Truvada, which combines the company’s anti-HIV medications Emtriva (emtricitabine) and Viread (tenofovir disoproxil fumarate) in one tablet, has now been granted marketing approval in all 25 member states

The plans have resulted from a strategic program review by the company’s management and board of directors and are part of a move to adopt a more focused

Atacand (candesartan cilexetil) is an angiotensin receptor blocker (ARB), manufactured under license from Takeda, that is already on the market for the treatment of high blood pressure. The

Data from a phase II clinical trial of ZAG-1701, EquiTech’s novel reformulated ibuprofen caplet, showed that ZAG-1701 is absorbed significantly faster and demonstrated a trend toward faster onset

Proteinase activated receptor (PAR-2) is a cell surface receptor known to play a critical role in mediating acute and chronic inflammation. EntreMed is developing a peptide that blocks

The research agreement between ChemGenex and Vernalis, which was signed in August 2004, has a value of approximately A$2 million ($1.6 million) in the first year following milestone

PDE10A is a class of phosphodiesterases that degrades cAMP and cGMP, molecules responsible for improving the function of many different cells in the body, including neurons. By inhibiting

The deal will transform Medco into the industry’s most comprehensive full-service pharmacy benefit provider, offering a broad spectrum of prescription medicines and integrated clinical services and support. Specialty